**************************************************************

MusclePharm Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, appointed Mariel Selbovitz, MPH, as Director of Global Therapeutics Product Procurement Development.

“We are thrilled to have Ms. Selbovitz join the MusclePharm team as we enter the therapeutic, nutritional supplementation market that is focused on products to meet the nutritional requirements of people living with HIV/AIDS,” stated Cory Gregory, MusclePharm’s President. “MusclePharm is working to greatly expand our sales of therapeutic, nutritional supplementation and provide increased help to people in need across the globe.”

Mr. Gregory continued, “We believe Ms. Selbovitz expertise and experience in the field of HIV will assist us secure distribution of MusclePharm products, such as Recon, to people living with the HIV disease in developing nations thru The Global Fund to Fight AIDS, Tuberculosis and Malaria, and The Presidents Emergency Plan for AIDS Relief (PEPFAR).”

The Global Fund to Fight AIDS, Tuberculosis and Malaria is an international financing institution that invests the world’s money to battle disease. To date, it has committed US$19.3 billion in 144 countries to support large-scale prevention, treatment and care programs against these three diseases.

“With Ms. Selbovitz extensive experience and assistance we plan to reach millions of people living with HIV in developing nations,” stated Dr. Roscoe Moore, former United States Surgeon General, and Chief Science Director for MusclePharm. “Participating in programs such as the Global Fund and PEPFAR and will enable MusclePharm to help counteract some of the devastating effects of HIV related nutritional deficiencies which greatly affect the immune system, as well as the growth and retention of muscle mass.”

Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced today that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.

Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

“We are very excited to be acquiring Rozetta-Cell Life Sciences,” stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. “Rozetta-Cell brings us a tremendous amount of complementary adult stem cell therapy technology, know-how and experience. With the addition of Rozetta-Cell, Power3 will significantly strengthen its IP portfolio in a major growth market by merging regenerative medicine with the technologies that we are using to identify disease-specific protein biomarkers and develop them into screening and diagnostic tests to address unmet medical needs.”

Forrester Research, Inc., (Nasdaq: FORR) will host three new role-focused Forums, furthering the company’s commitment to serving IT, marketing, and technology industry professionals through a role-based strategy. Forrester’s CIO Forum, Business Process & Application Delivery Forum, and Content & Collaboration Forum will take place October 7-8, 2010 at Gaylord National Resort & Convention Center in Washington, D.C.

“Role-based events are just one of the ways in which Forrester is positioned to address the unique challenges IT professionals face when trying to balance their day-to-day job with staying in front of the next big wave of technology change,” said Julie Meringer, managing director of Forrester’s IT client group. “Our focus on business technology enables attendees to capitalize on these changes and radically rethink the way they implement and manage IT.”

Forrester Research, Inc. is an independent research company that provides pragmatic and forward-thinking advice to global leaders in business and technology. Forrester works with professionals in 19 key roles at major companies providing proprietary research, customer insight, consulting, events, and peer-to-peer executive programs. For more than 27 years, Forrester has been making IT, marketing, and technology industry leaders successful every day.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp.(MSLP.OB).

**************************************************************

MusclePharm Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, announced today that MusclePharm athlete and NFL star Joey Porter will wear MusclePharm’s new clothing line during a 17-episode weekly series spanning the 2010 NFL season on NFL Network.

The new MusclePharm-branded hats and shirts will be unveiled to the retail market in the coming weeks and Porter’s notoriety in the world’s most popular sport presents an ideal platform to create exposure for the product line.

“At MusclePharm, we find creative ways to make our brand stand out to multiple audiences and in multiple formats to reach all consumers,” said Cory Gregory, MusclePharm’s President. “We currently have focused on brand awareness in marketing in the UFC, NFL, MLB and in action sports markets. We believe we are a company that crosses over to multiple demographics and helps all of these athletes in these different sports, while also appealing to the normal, everyday athlete.”

MusclePharm products are currently available in 1,200 of the top General Nutrition Centers (GNC) in the United States, as well as Vitamin Shop. MusclePharm’s award-winning products — Assault, Battle Fuel, Bullet Proof, Combat Powder, Recon and Shred Matrix—are also available online at gnc.com, bodybuilding.com, amazon.com and many other locations.

Bristol-Myers Squibb Company Co. (NYSE: BMY) was one of the first pharmaceutical companies to offer no-profit pricing for HIV/AIDS medicines in sub-Saharan Africa and low income countries. Today, more than 60 countries qualify for the BMS program. In addition, BMS engages in tiered pricing in middle-income countries based on a number of factors, including affordability and government commitment to care.

BMS was also one of the first companies to state that it would not enforce the patents it holds on Videx (didanosine) and Zerit (stavudine) in sub-Saharan Africa. Since 2001, the company has entered into eleven immunity-from-suit agreements for these products. In addition, BMS will offer requesting generic companies immunity-from-suit for Reyataz (atazanavir) in sub-Saharan Africa.

A pioneer in innovative technology transfer agreements, in 2006 BMS granted a royalty-free license to two generics companies, Aspen (located in Africa) and Emcure (located in India), to sell atazanavir in sub-Saharan Africa. BMS also transferred technical knowhow related to atazanavir manufacture and testing to these two generic companies, including training their personnel at BMS facilities as well as their respective manufacturing sites in Africa and India.

BMS has a longstanding commitment to increasing access to HIV medicines in resource-limited settings. BMS continues to stand by our partners in civil society and government in shared responsibility to expand access to HIV therapy. BMS will continue to pursue improvements in the treatment of HIV in the future and ensure that patients in need of treatment today can benefit from currently approved medicines.

Nature’s Sunshine Products, Inc. (NASDAQ:NATR), a leading manufacturer and marketer of nutritional supplements and complementary products, reports the resignation of Candace K. Weir from its Board of Directors. At the same time, the Company announced the appointment of Robert Mercer, an executive with 33 years in law and business, as a member of the Board of Directors, to serve as a Class II director and as a member of the Audit Committee.

Ms. Weir was originally appointed to the Board in 2009 as a Class II director. She was later elected by the Company’s shareholders to this same position during the 2009 Annual Meeting.

“We are very pleased to welcome Bob Mercer to our Board of Directors,” said Kristine F. Hughes, Nature’s Sunshine Chairman and a founder of the Company. “Bob brings extensive business operations and legal experience to Nature’s Sunshine and the Board that I know will benefit the Company and its shareholders, and his unique background also adds diversity to our Board. In addition, we would like to express our deep appreciation to Candace for her service as a director over the past year, and especially for the meaningful contributions she made to the Audit and Nominations Committees.”

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).

**************************************************************

MusclePharm Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, reported recently that the National Association of People with AIDS (NAPWA) is requesting the approval of MusclePharm’s Recon nutritional supplement to the New York State Medicaid list of prescription medications.

MusclePharm’s Recon Nutritional Supplement contains important amino acids, assisting in reaching the higher levels of nutrition required for people living with HIV. MusclePharm’s Recon Nutritional Supplement is easily digestible, helps the absorption of amino acids and proteins. It contains essential minerals, digestive enzymes, Glutamine and other metabolic agents that maximize recovery, protein synthesis and endurance.

“We are honored with the NAPWA’s support of therapeutic nutritional supplementation and look forward to the day when MusclePharm’s Recon is available to people living with HIV in New York State and all of those who depend on Medicaid for their therapeutic needs,” stated Brad Pyatt, MusclePharm’s Chief Executive Officer. “Our safe and scientific product formulations provide unique opportunities for us to expand MusclePharm’s distribution within the medical community. We believe this increased support continues to position MusclePharm as one of the leading developers and manufacturers of nutritional supplements.”

Nutritional Supplementation has long been utilized within the HIV community to maintain and support muscle mass and help strengthen the immune system. Whey protein has been shown thru various credible studies to aid in the growth of muscle mass. Unlike other Medicaid available proteins, MusclePharm’s Recon helps to burn fat while building muscle. This is a factor essential to people living with HIV, especially those on antiviral regimens where unwanted fat may be an issue in those who often battle muscle depletion.

EQ Labs, Inc. (Pink Sheets:EQLB) reports that poker superstar and celebrity spokesperson Vanessa Rousso appeared with Company CEO Mo Owens on the Las Vegas affiliate of ABC television (KTNV - Channel 13) promoting EQ Labs effervescent energy tablet.

Mr. Owens and Ms. Rousso announced a major promotion for Labor Day Weekend at the Convention Center location of Walgreens in Las Vegas for EQ Lab’s “Smart Energy Drink.” The company is expecting a very large audience on September 4, 2010. Each person that buys EQ at the Walgreens location that day wins a chance for a 1 hour personal poker boot-camp with Vanessa Rousso. The second winner will get a chance to ride in an off-road racing car with Baja racing champion TJ Flores.

On June 24, 2010, the company announced that Vanessa Rousso had signed an endorsement contract with EQ Labs. Ms. Rousso is a member of the prestigious Team PokerStars. In addition, she signed an endorsement contract as a celebrity spokesperson for Go Daddy in 2009. Ms. Rousso also appeared in the Sports Illustrated Swimsuit Issue.

Last week, EQ Labs CEO Maurice Owens was featured on “The Morning Blend” show talking about the virtues of EQ Energy drink while also displaying the company’s complete product line.

Mr. Owens commented, “Since I appeared on The Morning Blend show last, we have seen our sales accelerate throughout the Las Vegas region. Several retail locations have completely sold out of our product and we have received orders for more product. As Vanessa said on ‘The Morning Blend’ show, she is now using EQ at the poker tournaments that she appears in and it helps her to be on her game. We will be announcing more celebrity spokespeople in the near future.”

Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA), a beauty retailer with 356 retail stores, will conduct a conference call to discuss second quarter fiscal 2010 results on Thursday, September 2, 2010 at 5:00 p.m. Eastern Time / 4:00 p.m. Central Time. A press release detailing the Company’s second quarter fiscal 2010 results will be issued after the market closes and prior to the call. The conference call will be hosted by Lyn Kirby, Chief Executive Officer, Chuck Rubin, President and Chief Operating Officer and Gregg Bodnar, Chief Financial Officer.

Ulta is the largest beauty retailer that provides one-stop shopping for prestige, mass and salon products and salon services in the United States. Ulta provides affordable indulgence to its customers by combining the product breadth, value and convenience of a beauty superstore with the distinctive environment and experience of a specialty retailer. Ulta offers a unique combination of over 21,000 prestige and mass beauty products across the categories of cosmetics, fragrance, haircare, skincare, bath and body products and salon styling tools, as well as salon haircare products. Ulta also offers a full-service salon in all of its stores. The Company currently operates 356 retail stores across 38 states and also distributes its products through the Company’s website.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has received fifteen thousand dollars in cash from a third party (EEA, Inc ) for (7) days of advertising for EQ Labs, Inc. (EQLB.PK)

Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).

**************************************************************

MusclePharm Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, reports the appointment of Mariel Selbovitz, MPH, as Director of Global Therapeutics Product Procurement Development.

“We are thrilled to have Ms. Selbovitz join the MusclePharm team as we enter the therapeutic, nutritional supplementation market that is focused on products to meet the nutritional requirements of people living with HIV/AIDS,” stated Cory Gregory, MusclePharm’s President. “MusclePharm is working to greatly expand our sales of therapeutic, nutritional supplementation and provide increased help to people in need across the globe.”

Mr. Gregory continued, “We believe Ms. Selbovitz expertise and experience in the field of HIV will assist us secure distribution of MusclePharm products, such as Recon, to people living with the HIV disease in developing nations thru The Global Fund to Fight AIDS, Tuberculosis and Malaria, and The Presidents Emergency Plan for AIDS Relief (PEPFAR).”

PEPFAR was launched in 2003 by President George W. Bush, and is the largest effort by any nation to combat a single disease with $18 billion dollars dedicated to fight HIV/AIDS in developing nations over the five year period of 2003-2008. In the first five years of the program, PEPFAR focused on establishing and scaling up prevention, care and treatment programs. It achieved success in expanding access to HIV prevention, care and treatment in low-resource settings.

USANA Health Sciences (NASDAQ: USNA), a leader in nutritional supplement manufacturing, will be one of the first companies in the industry to utilize Nutritional Hybrid Technology. This cutting-edge manufacturing method was unveiled to thousands of USANA independent Associates in attendance at the company’s international convention.

Through Nutritional Hybrid Technology, USANA can now combine two distinct formulas into one bilayered tablet, allowing for advanced ingredient combinations while providing product stability. The technology will also help consumers simplify their nutritional regimen by decreasing the number of tablets they take each day. Two new USANA formulas, Proflavanol C100 and Hepasil DTX, were created with the new manufacturing technology and also unveiled at the company’s convention.

Proflavanol C100 combines powerful proanthocyanidins from grape-seed extract with high-potency vitamin C to promote sound cardiovascular health, immune function, and healthy-looking skin. An in-house USANA study found that the combination of grape-seed extract and vitamin C in Proflavanol C100 provides long-term antioxidant activity and better protective effects than if they were not combined.

USANA’s upgraded Hepasil DTX formula contains a proprietary blend of ingredients to maintain optimum liver support and aid in the body’s detoxification processes. Nutritional Hybrid Technology allows USANA to boost key ingredients in the supplement while maintaining product quality and stability.

Herbalife Ltd. (NYSE:HLF) announced three sponsorship agreements to extend its branding efforts around the world.

The company became an official sponsor of top Israeli football team, Maccabi Haifa FC. As Official Sponsor for Sports Nutrition, Herbalife will work with the team’s doctors to provide nutritional advice and products to the team as part of their overall training regimen.

The two-year deal will see the Herbalife logo appear on all Maccabi Haifa match and training kit shorts. In addition, the Herbalife brand will be showcased in the Kiryat Eliezer, Maccabi Haifa’s home stadium, and in the team’s training facilities; as well as through Maccabi Haifa’s official media channels and on the team bus.

The company signed India’s MC Mary Kom, the four-time world boxing champion and ambassador for the International Boxing Association, as a sponsored athlete for its nutritional range of products. Kom is the recipient of the Rajiv Gandhi Khel Ratna, the Padma Shri and the Arjuna Award, which are given to those who excel in their field. She is also recognized as one of India’s foremost medal hopes at the 2012 London Olympics. Her training and preparation for the Olympics is supported by the Olympic Gold Quest (OGQ), a not-for-profit foundation set up with the mission of winning Olympic gold medals for the country. The OGQ was started by Indian sports legends Geet Sethi and Prakash Padukone.

In addition to Kom in India, Herbalife renewed its agreement with badminton pro Saina Nehwal, The Badminton World Federation recently ranked Nehwal number 3 in the world after she clinched the winning titles back to back at the India Open Grand Prix, the Singapore Open Super Series and the Indonesia Open Super Series. Nehwal has been associated with Herbalife since 2009.

Along with its independent distributors, Herbalife sponsors 150 athletes, fitness and sporting events around the world including FC Barcelona, LA Galaxy.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).

**************************************************************

MusclePharm Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, reports the appointment of Mariel Selbovitz, MPH, as Director of Global Therapeutics Product Procurement Development.

“We are thrilled to have Ms. Selbovitz join the MusclePharm team as we enter the therapeutic, nutritional supplementation market that is focused on products to meet the nutritional requirements of people living with HIV/AIDS,” stated Cory Gregory, MusclePharm’s President. “MusclePharm is working to greatly expand our sales of therapeutic, nutritional supplementation and provide increased help to people in need across the globe.”

Mr. Gregory continued, “We believe Ms. Selbovitz expertise and experience in the field of HIV will assist us secure distribution of MusclePharm products, such as Recon, to people living with the HIV disease in developing nations thru The Global Fund to Fight AIDS, Tuberculosis and Malaria, and The Presidents Emergency Plan for AIDS Relief (PEPFAR).”

The Global Fund to Fight AIDS, Tuberculosis and Malaria is an international financing institution that invests the world’s money to battle disease. To date, it has committed US$19.3 billion in 144 countries to support large-scale prevention, treatment and care programs against these three diseases.

PEPFAR was launched in 2003 by President George W. Bush, and is the largest effort by any nation to combat a single disease with $18 billion dollars dedicated to fight HIV/AIDS in developing nations over the five year period of 2003-2008. In the first five years of the program, PEPFAR focused on establishing and scaling up prevention, care and treatment programs. It achieved success in expanding access to HIV prevention, care and treatment in low-resource settings.

By securing procurement of the Global Fund and PEPFAR, MusclePharm will be able to distribute Recon and other supplements to millions of people with HIV/AIDS worldwide thru government funds. In July 2010, MusclePharm presented at the 18th International AIDS Conference on the benefits of Recon in people with HIV/AIDS, sponsored by the National Association of People with AIDS (NAPWA) and the AIDS Institute, both leading HIV legislative and advocacy organizations.

Selbovitz is a member of the Cornell AIDS Clinical Trials Group Community Advisory Board and AIDS Treatment Advocacy Coalition. She presented at the 5th European Conference on Clinical and Social Research on AIDS and Drugs, International Conference on Antiviral Research, 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention and XVIII International AIDS Conference.

Merck & Company (NYSE:MRK) reports that the Merck Company Foundation and the Bill & Melinda Gates Foundation are committing an additional $60 million to support Botswana’s African Comprehensive HIV/AIDS Partnerships (ACHAP). Merck is known as MSD outside the US and Canada. A unique program developed with and led by the Government of Botswana, ACHAP is one of sub-Saharan Africa’s oldest, most successful public-private partnerships. With today’s pledge, the Merck Foundation and the Gates Foundation’s total cash contributions now amount to $166.5 million. Merck will also continue the donation of its HIV medicines.

Building on the successes created by its initial investment of $56.5 million nine years ago, Merck will contribute an additional $30 million over the next five years. The new funding will continue the program’s original efforts in treatment and care but also will support the second phase initiatives to meet the current treatment needs of the 137,000 Batswana (people from Botswana) living with HIV and new patients enrolled in the second phase. The second phase initiatives include: the prevention of HIV, the critical need to treat people living with HIV for tuberculosis (TB) and the sustainability of the program to allow Botswana to successfully address HIV/AIDS within its own borders.

“For nearly 10 years, Merck has been a partner in helping the Government of Botswana save the lives of thousands of people living with HIV and AIDS and we are confident our new funding will continue to contribute to the well-being of the country,” said Richard T. Clark, chairman and CEO of Merck. “This collaboration is a great success story on many levels, and has become a model for many countries both on and off the African continent.”

ACHAP has helped demonstrate how public-private partnerships might work to save the lives of the world’s poorest people infected with HIV. Between 2001 and 2007, the partnership has supported Botswana in preventing the estimated deaths of more than 53,000 Batswana living with HIV. Today about 90 percent of Batswana living with HIV receive treatment, compared to less than 5 percent when the program began in 2001.

“Our partners’ contributions, through funding, antiretroviral (ARV) medicine donations and medical expertise, have been absolutely essential to our ability to address the needs of Batswana living with HIV and AIDS,” said Themba Moeti, M.D., managing director of ACHAP. “We look forward to strengthening our partnership as we enter our second phase and enhancing the successes of our first decade while responding to the challenges that remain and retaining the flexibility to address emerging issues.”

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).